| Objective:To evaluate the clinical efficacy and survival analysis of apatinib combined with docetaxel and docetaxel in the treatment of advanced non-small cell lung cancer were comPared in order to guide clinical medication and provide evidence-based medicine for ataPinib in the treatment of advanced non-small cell lung cancer.Methods:To choose 93 patients with non-small cell lung cancer who were hospitalized in the Department of oncology in our hospital were confirmed by histopathological or cytological diagnosis from Jun.2016 to Jun.2017.All of the 93 patients with advanced non-small cell lung cancer who had no indications of radical resection of lung cancer were stage III A-IV.The selected subjects were divided into groups.45 Patients treated with apatinib and docetaxel were used as observation group.48 Patients with docetaxel single drug treatment were used as control group.The basic information of age,sex and occuPation in two groups of patients was collected,and the treatment efficiency and side effects of the two groups were analyzed.The changes in the size,number and position of the tumor were observed before and 12 months after the two groups of treatment.At the same time,the two groups of patients after treatment were followed up every 12 months to record the changes of clinical symptoms and toxic and side effects.Results:1.The basic data of the two groups the general data The difference of the age,sex,occupation,number of lesions,type of primary tumors,location of tumors,pathological classification,clinical stage,lymph node metastasis and distant metastasis of the two groups was not statistically significant,and the two groups were comparable(P>0.05).2.Compared of the PS scores of the two groups before and after treatment There was no significant difference between the two groups before and after treatment(P<0.05).After treatment,the difference of the PS scores of the two groups was statistically significant((P<0.05)).The scores of the patients in the treatment group were lower than those in the control group.The PS score was used to evaluate the curative effect after treatment.The effective rate of the control group was 56.25%,and that of the treatment group was 95.56%.There was a significant difference between the two groups(x~2=19.276,P<0.05).3.Compared of the health status scores of the two groups before and after treatment were compared,.There was no significant difference between the two groups before and after treatment(P>0.05).After treatment,the difference of the scores of the two groups was statistically significant(P<0.05).4.The effective rate of PS score in general health status of the two groups The effective rate of PS score was 56.25%in the control group and 95.56%in the treatment group.The efficacy of PS score in the two groups was compared,2,with statistical significance(x~2=19.531,P<0.001).5.Compared of the remission rate of solid tumors for two groups The remission rate of solid tumors in the treatment group was 42 cases(93.33%)and that in the control group was 44 cases(91.67%).The remission rate of the two groups after treatment was compared,,the difference was statistically significant(x~2=48.743,P<0.001).6.Comparing the occurrence of side effects after treatment between the two groups The common adverse reactions in the treatment group and the control group were fever,nausea and vomiting,hemoglobin reduction,leukopenia,thrombocytopenia and neutropenia.There was no significant difference in fever,nausea and vomiting,hemoglobin reduction,leukopenia,thrombocytopenia and neutropenia between the two groups(P>0.05).The proportion of fever,nausea and vomiting between the two groups was P>0.05,with no significant difference.The incidence of fever,nausea,vomiting,hemoglobin reduction,leukopenia,thrombocytopenia and neutropenia in the treatment group and the control group were all higher than 0.05,with no significant difference.The incidence of neutropenia in the treatment group was significantly higher than that in the control group(P<0.05).7.Analysis of survival in two groups of patients The patients of two groups were followed up for 10-24 months.The quality of life of the patients in the treatment group was(51.62±4.90),the quality of life of the control group was(40.02±6.97),and the score of life and life in the two groups was compared,t=9.227,and P=0.000.The quality of life in the treatment group was higher than that in the control group.The progression-free survival time was(20.91±2.47)21 months,the 6-month progression-free survival rate was 100.00%,and the 1-year progression-free survival rate was 100%in the treatment group.The progression-free survival time was(14.85±2.41)months,the 6-month progression-free survival rate was 100.00%,and the one-year progression-free survival rate was 85.42%in the control group.The progression-free survival time of the treatment group and the control group was11.960,P<0.001,the difference was statistically significant.It showed that the median progression-free survival time was statistically significant(?~2=75.671,P<0.001)by Log-Rank test.The median progression-free survival time of the treatment group was longer than that of the control group.Conclusions:1.The total control rate and total stability rate of apatinib combined with docetaxel in the treatment of advanced non-small cell lung cancer are much higher than those of docetaxel alone,especially in stage IIIA and stage IIIB.The general health PS score of patients is better than that of conventional chemotherapy group.2.The toxicity and side effects of apatinib combined with docetaxel in the treatment of advanced non-small cell lung cancer are generally mild and transient,mainly below grade 3.There is no difference between the incidence of different side effects and that of docetaxel alone,suggesting that the safety of combined therapy is more reliable.3.The median progression-free survival time,6-month progression-free survival rate and 1-year progression-free survival rate of patients with advanced non-small cell lung cancer treated with apatinib combined with docetaxel were higher than those treated with single drug,suggesting that the effect of combination therapy is obvious and the life expectancy of patients can be increased. |
PDF Full Text Request